Baiyunshan Pharmaceutical Gets Regulatory Approval to Amend Drug Production License

MT Newswires Live02-13

Guangzhou Baiyunshan Pharmaceutical (SHA:600332) subsidiary Hejigong Pharmaceutical Factory received approval from Guangdong's drug administrator to amend its drug production license.

The amendment involves the reduction of the "F Building Production Line" at the Xingzhou manufacturing department located at 4 South Chuangye Ave., Mingzhu Industrial Park in Guangzhou, according to a Wednesday filing with the Shanghai bourse.

The F Building Production Line was primarily used for the pre-processing and extraction of traditional Chinese medicine. The adjustment is part of the company's efforts to optimize resource allocation and maintain stable production capacity to meet market demands.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2511550768?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-02-13 11:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2511550768","market":"us","top_or_hot":-1,"title":"Baiyunshan Pharmaceutical Gets Regulatory Approval to Amend Drug Production License","media":"MT Newswires Live","content":"<html><body><p> Guangzhou Baiyunshan Pharmaceutical (SHA:600332) subsidiary Hejigong Pharmaceutical Factory received approval from Guangdong's drug administrator to amend its drug production license.</p><p>The amendment involves the reduction of the \"F Building Production Line\" at the Xingzhou manufacturing department located at 4 South Chuangye Ave., Mingzhu Industrial Park in Guangzhou, according to a Wednesday filing with the Shanghai bourse.</p><p>The F Building Production Line was primarily used for the pre-processing and extraction of traditional Chinese medicine. The adjustment is part of the company's efforts to optimize resource allocation and maintain stable production capacity to meet market demands.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Baiyunshan Pharmaceutical Gets Regulatory Approval to Amend Drug Production License</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBaiyunshan Pharmaceutical Gets Regulatory Approval to Amend Drug Production License\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-02-13 11:14</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Guangzhou Baiyunshan Pharmaceutical (SHA:600332) subsidiary Hejigong Pharmaceutical Factory received approval from Guangdong's drug administrator to amend its drug production license.</p><p>The amendment involves the reduction of the \"F Building Production Line\" at the Xingzhou manufacturing department located at 4 South Chuangye Ave., Mingzhu Industrial Park in Guangzhou, according to a Wednesday filing with the Shanghai bourse.</p><p>The F Building Production Line was primarily used for the pre-processing and extraction of traditional Chinese medicine. The adjustment is part of the company's efforts to optimize resource allocation and maintain stable production capacity to meet market demands.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"600332","symbol_name":"白云山","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2511550768","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2511550768","pubTimestamp":1739416481,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Guangzhou Baiyunshan Pharmaceutical  subsidiary Hejigong Pharmaceutical Factory received approval from Guangdong's drug administrator to amend its drug production license.The amendment involves the reduction of the \"F Building Production Line\" at the Xingzhou manufacturing department located at 4 South Chuangye Ave., Mingzhu Industrial Park in Guangzhou, according to a Wednesday filing with the Shanghai bourse.The F Building Production Line was primarily used for the pre-processing and extraction of traditional Chinese medicine. The adjustment is part of the company's efforts to optimize resource allocation and maintain stable production capacity to meet market demands.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600332":"白云山","BK0183":"MSCI概念","BK0012":"证金概念","BK0028":"国家队","BK0239":"医药制造","BK0196":"行业龙头","BK0097":"医药电商","BK0175":"白马股","BK0096":"民营医院","BK0070":"员工持股","BK0188":"融资融券"},"translate_title":"白云山药业获监管批准修改药品生产许可证","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600332":0.9},"content_text":"Guangzhou Baiyunshan Pharmaceutical (SHA:600332) subsidiary Hejigong Pharmaceutical Factory received approval from Guangdong's drug administrator to amend its drug production license.The amendment involves the reduction of the \"F Building Production Line\" at the Xingzhou manufacturing department located at 4 South Chuangye Ave., Mingzhu Industrial Park in Guangzhou, according to a Wednesday filing with the Shanghai bourse.The F Building Production Line was primarily used for the pre-processing and extraction of traditional Chinese medicine. The adjustment is part of the company's efforts to optimize resource allocation and maintain stable production capacity to meet market demands.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2511550768"}